Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial.

[1]  I Syndikus,et al.  Alpha emitter radium-223 and survival in metastatic prostate cancer. , 2013, The New England journal of medicine.

[2]  T. Delea,et al.  Healthcare utilization and costs associated with skeletal-related events in prostate cancer patients with bone metastases , 2012, Prostate Cancer and Prostatic Diseases.

[3]  P. Hoskin,et al.  Targeted radio-nuclide therapy of skeletal metastases. , 2013, Cancer treatment reviews.

[4]  E. Basch,et al.  Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial. , 2012, The Lancet. Oncology.

[5]  Kurt Miller,et al.  Increased survival with enzalutamide in prostate cancer after chemotherapy. , 2012, The New England journal of medicine.

[6]  E. Basch,et al.  End points and outcomes in castration-resistant prostate cancer: from clinical trials to clinical practice. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  M L Kilgore,et al.  Mortality following bone metastasis and skeletal-related events among men with prostate cancer: a population-based analysis of US Medicare beneficiaries, 1999–2006 , 2011, Prostate Cancer and Prostatic Diseases.

[8]  M. Carducci,et al.  Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study , 2011, The Lancet.

[9]  P. Hoskin,et al.  Combining systemic bisphosphonates with palliative external beam radiotherapy or bone-targeted radionuclide therapy: interactions and effectiveness. , 2009, Clinical oncology (Royal College of Radiologists (Great Britain)).

[10]  K. Anstrom,et al.  Effects of skeletal morbidities on longitudinal patient-reported outcomes and survival in patients with metastatic prostate cancer , 2006, Supportive Care in Cancer.

[11]  S. Nilsson,et al.  High-Linear Energy Transfer Irradiation Targeted to Skeletal Metastases by the α-Emitter 223Ra: Adjuvant or Alternative to Conventional Modalities? , 2006, Clinical Cancer Research.

[12]  V. Lewington,et al.  Bone-seeking radionuclides for therapy. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[13]  I. Tannock,et al.  Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. , 2004, The New England journal of medicine.

[14]  F. Saad,et al.  Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. , 2004, Journal of the National Cancer Institute.

[15]  G. Roodman.  Mechanisms of bone metastasis. , 2004, Discovery medicine.

[16]  R. Vessella,et al.  Mechanisms, Hypotheses and Questions Regarding Prostate Cancer Micrometastases to Bone , 1998, Cancer and Metastasis Reviews.

[17]  P. Grambsch,et al.  Penalized Survival Models and Frailty , 2003 .

[18]  J. Roeske,et al.  Targeting of osseous sites with alpha-emitting 223Ra: comparison with the beta-emitter 89Sr in mice. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[19]  F. Saad,et al.  A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. , 2002, Journal of the National Cancer Institute.

[20]  G. Henriksen,et al.  Significant antitumor effect from bone-seeking, alpha-particle-emitting (223)Ra demonstrated in an experimental skeletal metastases model. , 2002, Cancer research.

[21]  R. Coleman.  Metastatic bone disease: clinical features, pathophysiology and treatment strategies. , 2001, Cancer treatment reviews.